<DOC>
	<DOCNO>NCT01856283</DOCNO>
	<brief_summary>This multicentre , single-arm study nilotinib 300 mg BID newly diagnose patient CP-CML . This study design establish disappearance Ph+ stem cell ( CD34+/lin- ) BM nilotinib treatment . In addition , study investigator aim perform Gene Expression Profiling ( GEP ) CML enrol patient use Affymetrix GeneChip Instruments Software Systems , Affymetrix GeneChip Human Genome U133 Plus 2.0 ( whole human transcriptome analysis ) diagnosis 3 different time point treatment Nilotinib ( 3 , 6 , 12 month ) .</brief_summary>
	<brief_title>Nilotinib 300 mg BID Newly Diagnosed CP-CML Patients Verify Disappearance CD34+/Lin-Ph+ Cells</brief_title>
	<detailed_description>This study design establish disappearance Ph+ stem cell ( CD34+/lin- ) BM nilotinib treatment . The primary efficacy endpoint measure rate CD34+/lin-Ph+ cell BM 6 month treatment . In order obtain result , BM blood enrol patient store 6 month treatment nilotinib . The isolated CD34+/lin- cell employed standard FISH analysis . These endpoint obtain central laboratory Niguarda Ca ' Granda Hospital , Milano , Italy . Secondary endpoint reach performing : - analyze CD34+/lin- cell diagnosis , 3 12 month treatment ; - cytogenetic analysis estimate rate CCyR 3 , 6 12 month ; analysis perform local laboratory ; - molecular analysis determinate rate MR ( ≤ 10 % , ≤ 1 % , MMR , MR4,5 IS ) 3 , 6 12 month peripheral blood ; molecular analysis perform use Labnet standardized laboratory Lombardy .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<criteria>Male female patient diagnosis CPCML cytogenetic confirmation Ph chromosome ( 9 ; 22 ) translocation within 3 month diagnosis Patients Ph negative variant translocation standard cytogenetic analysis Ph positive FISH , eligible well Age ≥ 18 year old ( upper age limit give ) WHO performance status ≤2 Normal serum level ≥ LLN ( low limit normal ) potassium , magnesium , total calcium correct serum albumin phosphorus , correctable within normal limit supplement , prior first dose study medication AST ALT ≤ 2.5 x ULN ≤ 5.0 x ULN consider due leukaemia Alkaline phosphatase ≤ 2.5 x ULN unless consider due leukaemia Total bilirubin ≤ 1.5 x ULN , except know Mb Gilbert Serum lipase amylase ≤ 1.5 x ULN Serum creatinine ≤ 1.5 x ULN Written inform consent sign prior study procedure perform Pretreatment HU &gt; 3 month imatinib permit Prior accelerate phase include clonal evolution blast crisis Contraindication excipients study medication impaired cardiac function include follow : 1 . LVEF &lt; 45 % 2 . Complete leave bundle branch block 3 . Right bundle branch block plus leave anterior hemiblock , bifascicular block 4 . Use ventricularpaced pacemaker 5 . Congenital long QT syndrome 6 . Clinically significant ventricular atrial tachyarrhythmias 7 . Clinically significant rest bradycardia ( &lt; 50 beat per minute ) 8 . QTcF &gt; 450 msec screen ECG.If QTcF &gt; 450 msec electrolyte within normal range nilotinib dose , electrolyte correct patient rescreened QTcF criterion 9 . Myocardial infarction within 12 month prior start nilotinib 10 . Other clinical significant heart disease ( e.g . unstable angina , congestive heart failure , uncontrolled hypertension ) Acute ( i.e . within 1 year start study medication ) chronic pancreatitis Concurrent uncontrolled medical condition ( e.g . uncontrolled diabetes , active uncontrolled infection , acute chronic liver renal disease ) could cause unacceptable safety risk compromise compliance protocol Impaired gastrointestinal function disease may alter absorption study drug ( e.g.ulcerative disease , uncontrolled nausea , vomit diarrhea , malabsorption syndrome , small bowel resection gastric bypass surgery ) Concomitant medication potential QT prolongation ( see link complete list : http : //www.torsades.org/medicalpros/druglists/printabledruglist.cfm ) Concomitant medication know strong inducer inhibitor CYP450 Isoenzyme CYP3A4 : see link complete list ( http : //medicine.iupui.edu/flockhart/table.htm ) Patients undergone major surgery ≤ 2 week prior start study drug recover side effect therapy Patients pregnant breast feed woman reproductive potential employ effective method birth control.Women childbearing potential must negative serum pregnancy test within 14 day prior administration nilotinib.Post menopausal woman must amenorrheic least 12 month order consider nonchildbearing potential.Female patient must agree employ effective barrier method birth control throughout study 3 month follow discontinuation study drug Treatment haematopoietic colonystimulating growth factor ( e.g . GCSF , GMCSF ) ≤1 week prior start study drug Known diagnosis human immunodeficiency virus ( HIV ) infection ( HIV test mandatory ) Patients history another primary malignancy currently clinically significant currently require active intervention Patients unwilling unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>